Michael Mason - Feb 27, 2024 Form 4 Insider Report for Karyopharm Therapeutics Inc. (KPTI)

Role
EVP, CFO & Treasurer
Signature
/s/Nancy Smith as Attorney-in-Fact for Michael Mason
Stock symbol
KPTI
Transactions as of
Feb 27, 2024
Transactions value $
-$3,369
Form type
4
Date filed
2/29/2024, 05:35 PM
Previous filing
Feb 8, 2024
Next filing
Mar 4, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KPTI Common Stock Sale -$3.37K -2.55K -1.03% $1.32 244K Feb 27, 2024 Direct F1
transaction KPTI Common Stock Award $0 +188K +77.01% $0.00 433K Feb 28, 2024 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 10, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units ("RSUs"). The sale does not represent a discretionary trade by the reporting person.
F2 Represents the award of RSUs pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in three equal annual installments beginning February 28, 2025.